Examination of the Effect of Nocturia on Pelvic Floor Symptoms, Sleep Parameters and Quality of Life in Women with Urinary Incontinence
1 other identifier
observational
102
1 country
1
Brief Summary
Urinary incontinence (UI), a common issue, is the involuntary leakage of urine that negatively affects individuals socially, physically, and psychologically, leading to a decreased quality of life. Nocturia, which is often seen alongside UI, has similar adverse effects. Nocturia refers to the number of urinations during the main sleep period, and it should be accompanied by the intention to fall back asleep after waking up. Nocturia can arise from factors such as sleep disorders and circadian rhythm disturbances. The circadian rhythm regulates the body's biological functions, and this rhythm varies from person to person, creating chronotypes. There is a strong relationship between sleep and nocturia because nocturia leads to deep sleep loss, an increased risk of metabolic diseases, decreased sleep quality and sleep efficiency, and an increase in the number of awakenings after sleep onset. It is necessary to distinguish whether nocturia, which has a comprehensive impact, affects pelvic floor symptoms, chronotype, sleep quality, fatigue, sleepiness, and quality of life in women with UI. Therefore, the aim of this study is to examine the effect of nocturia on pelvic floor symptoms, chronotype, sleepiness, sleep quality, fatigue, and quality of life in women with UI.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedFirst Submitted
Initial submission to the registry
February 26, 2025
CompletedFirst Posted
Study publicly available on registry
March 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedMarch 10, 2025
March 1, 2025
4 months
February 26, 2025
March 4, 2025
Conditions
Outcome Measures
Primary Outcomes (5)
Assessment of Symptoms
To determine the discomfort caused by pelvic floor dysfunction symptoms, the "Global Pelvic Floor Discomfort Questionnaire" will be used. The Global Pelvic Floor Discomfort Questionnaire consists of 9 questions. The score obtained from the scale ranges from 0 to 45, and to convert this score to a percentage, the total score is averaged and then multiplied by 20. As the score on the scale increases, the severity of the discomfort also increases.
from January 2025 to April 2025
Assessment of Symptoms
To determine the discomfort caused by pelvic floor dysfunction symptoms, the "Urogenital Distress Inventory-6" will be used. The Urogenital Distress Inventory is a Likert-type scale consisting of 6 questions. The score obtained from the scale ranges from 0 to 18, and the score is converted into a percentage. As the score on the scale increases, the severity of the discomfort also increases.
from January 2025 to April 2025
Assessment of Sleep Quality
Pittsburgh Sleep Quality Index will be used.Pittsburgh Sleep Quality Index scale has seven sub-scales that portray various domains of sleep: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Responses for each subscale are scored as 0-3. Having a global score of 5 or higher indicates bad sleep quality. sleepiness.
from January 2025 to April 2025
Assessment of Chronotype
Chronotype assessment will be evaluated using the "Morningness-Eveningness Questionnaire." The questionnaire consists of 19 questions. It has a five-point scale, with each range corresponding to a different chronotype. Individuals who score between 70-86 are classified as "definitely morning type," those who score between 59-69 are classified as "closer to morning type," those who score between 42-58 are classified as "intermediate type," those who score between 31-41 are classified as "closer to evening type," and individuals who score between 16-30 are classified as "definitely evening type."
from January 2025 to April 2025
Assessment of Quality of life
Quality of life will be assessed using the CONTILIFE Questionnaire. The questionnaire is a Likert-type scale consisting of 28 questions and includes six subparameters. Questions 1-7 assess daily activities, questions 8-11 assess effort, questions 12-18 assess self-esteem, questions 19-24 assess emotional impact, questions 25-27 assess sexuality, the 28th question is used to evaluate general quality of life.The total score is determined by summing the scores from all subparameters. As the total score increases, it indicates a poorer quality of life.
from January 2025 to April 2025
Secondary Outcomes (2)
Assessment of Sleepiness
from January 2025 to April 2025
Assessment of Fatigue
from January 2025 to April 2025
Study Arms (2)
Group with nocturia
Women who experience urinary incontinence and have nocturia.
Group without nocturia
Women who experience urinary incontinence but do not have nocturia.
Eligibility Criteria
Gülhane Training and Research Hospital, Department of Obstetrics and Gynecology
You may qualify if:
- Being 18 years of age or older
- Being female
- Have been diagnosed with urinary incontinence
- Wake up during the main sleep period to relieve the need to urinate, with the intention of returning to sleep or falling asleep again after each urination
- Being 18 years of age or older
- Being female
- Have been diagnosed with urinary incontinence
You may not qualify if:
- Diagnosis of a sleep disorder
- Diagnosis of any neurological disease
- Chronic kidney disease
- Diagnosis of diabetes
- Use of sleep medications
- Use of antidepressants
- Use of diuretic medications
- Use of any medication for urinary incontinence
- Hormone replacement therapy
- Pregnancy or having given birth within the last six months
- Having had a urinary tract infection in the last three months
- Presence of prolapse greater than stage 2
- History of orthopedic trauma to the pelvic region
- Pelvic surgery within the last six months
- History of cancer
- +16 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Health Sciences Gülhane Faculty of Physiotherapy and Rehabilitation
Ankara, Keçiören, 06000, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
February 26, 2025
First Posted
March 10, 2025
Study Start
January 1, 2025
Primary Completion
May 1, 2025
Study Completion
June 1, 2025
Last Updated
March 10, 2025
Record last verified: 2025-03